An interventional study of Bariatric surgery in Morbid Obesity, Bariatric Surgery and Malnutrition, sponsored by El-Sahel Teaching Hospital. Active, not recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by El-Sahel Teaching Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Obesity, Morbid with a site in Egypt — 12 open to participants now, 16 under way, none of them phase 3. Obesity, Morbid · Egypt.
Among the 76 studies in Obesity, Morbid with a site in Egypt, this one is the 59th largest by planned enrollment of the 69 interventional ones that give a count, is one of 7 that started in 2024, is one of 56 with no phase, reaches primary completion later than 8 of the 15 other live ones, and was the 62nd registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →12 of the 76 studies in Obesity, Morbid with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 18–45 · Women only
Cairo University · Sites in Egypt
Ages 18–60
Cairo University · Sites in Egypt
Ages 18–65
Alexandria University · Sites in Egypt
Ages 20–60 · Healthy volunteers
Zagazig University · Sites in Egypt
Ages 18–50 · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 3 · Phase 4 6
First in 2010; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Median enrollment 90 across the 69 interventional studies, 66 across the 7 observational. Of the 47 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 76 has an industry lead sponsor. The 10 most frequent:
El-Sahel Teaching Hospital is the lead sponsor of 3 studies on the registry; none are open to participants now.
El-Sahel Teaching Hospital has 1 study filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
4 of the studies in Obesity, Morbid with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07397572Cairo UniversityIron Supplementation and Anemia After Sleeve Gastrectomy | 2026-11 |
| NCT07461610Cairo UniversityStool Analysis After Sleeve Gastrectomy vs Gastric Bypass | 2026-11 |
| NCT07446972Cairo UniversityImpact of Bariatric Surgery on Female Sexual Function and Sex Hormones | 2026-12 |
| NCT07289555El-Sahel Teaching HospitalTailored Stapled SADI-S: Initial Report and Preliminary Results | 2026-12-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 76 studies in Obesity, Morbid with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obesity is a serious health problem worldwide and can lead to many diseases such as diabetes, high blood pressure, heart disease, and sleep apnea. When lifestyle changes and medications are not enough, metabolic and bariatric surgery (MBS) is currently the most effective and long-lasting treatment option.
This study focuses on one of the newer types of bariatric surgery called Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S). This procedure combines two parts:
Sleeve gastrectomy, which reduces the size of the stomach so the patient feels full after eating a small amount.
Duodeno-ileal bypass, which shortens the path food takes through the small intestine to reduce calorie absorption.
Our hospital's surgical team is studying a tailored version of this operation, where the length of the bypassed intestine is adjusted to each patient's anatomy. We believe this personalized approach may improve weight loss results while lowering the risk of vitamin and nutrient deficiencies.
The study will include 40 adult patients with obesity who are undergoing SADI-S surgery, either as their first weight loss operation or as a revision surgery after an earlier sleeve gastrectomy. During the operation, surgeons will measure the total length of each patient's small intestine and use a formula to decide how much of it should be bypassed. The duodeno-ileal connection will be made using a stapled technique, which is expected to be safe and efficient.
After surgery, patients will be followed regularly at 1, 3, 6, 9, and 12 months, and then once per year. At each visit, the study team will monitor weight loss, body mass index (BMI), resolution of diabetes and other obesity-related conditions, nutritional status (including vitamins and minerals), and any side effects such as diarrhea, reflux, or nutritional problems.
The goal of this study is to learn whether this tailored SADI-S technique can provide strong, sustained weight loss and health improvement with fewer long-term complications. The results will help improve surgical planning for future patients by showing whether measuring and customizing the bypass length is safer and more effective than using a fixed length.
All data collected will be kept confidential. Patients' participation in the study will not change their regular care or follow-up, and they can withdraw at any time without affecting their treatment.
Background and Rationale
With obesity rates increasing globally, metabolic and bariatric surgery (MBS) has emerged as the most effective long-term treatment for severe obesity and its related comorbidities such as type 2 diabetes mellitus, hypertension, dyslipidemia, and obstructive sleep apnea. Among the various procedures, laparoscopic sleeve gastrectomy (LSG) and Roux-en-Y gastric bypass (RYGB) have been the most frequently performed worldwide. However, the field continues to evolve with the introduction of newer, simplified techniques that aim to achieve optimal weight loss and metabolic control with lower complication rates and better nutritional safety profiles.
Single-Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S), first described by Sánchez-Pernaute and Torres in 2007, is a simplified derivative of the biliopancreatic diversion with duodenal switch (BPD-DS). This operation combines the restrictive component of sleeve gastrectomy with a single duodenoileal bypass, eliminating one anastomosis compared with the traditional DS. By preserving the pylorus, SADI-S maintains the physiological passage of food and minimizes dumping syndrome, postprandial hypoglycemia, and bile reflux.
Initially, the common channel length was set at 200 cm but was later extended to 250-300 cm to reduce the risk of excessive malabsorption and protein-calorie malnutrition. SADI-S has since demonstrated excellent outcomes in terms of weight loss, diabetes remission, and comorbidity improvement, with acceptable nutritional safety when the bypassed segment is appropriately chosen. The International Federation for the Surgery of Obesity (IFSO) and the American Society for Metabolic and Bariatric Surgery (ASMBS) have both recognized SADI-S as a validated bariatric procedure.
However, despite the growing evidence base, the optimal limb length configuration remains controversial. Most studies use fixed bypass lengths without accounting for wide interindividual variability in total small bowel length (SBL), which can range from 350 to over 1000 cm. Because SBL strongly influences caloric absorption and nutritional outcomes, a "one-size-fits-all" approach may lead to imbalanced results-either inadequate weight loss or excessive malabsorption. Measurement inconsistencies, different starting points for limb calculation, and frequent omission of total SBL assessment further complicate standardization.
Tailoring the bypass limb as a proportion of the measured total bowel length may yield more physiologically balanced results and reduce nutritional complications. Despite concerns that intraoperative measurement prolongs surgery, experienced laparoscopic surgeons can measure SBL efficiently, adding only a few minutes to operative time.
Another point of technical variation in SADI-S relates to the anastomotic technique. The duodeno-ileal anastomosis is technically more demanding than gastrojejunal anastomoses performed in RYGB or OAGB because of the thin duodenal wall and proximity to the pancreas and bile duct. While both hand-sewn and stapled techniques are described, stapled anastomosis is increasingly favored for its reproducibility, shorter operative time, and lower reported rates of leakage and stenosis.
Study Rationale
This prospective observational study aims to evaluate a tailored, stapled SADI-S technique in which the length of the biliopancreatic limb (BPL) is calculated as a fixed percentage (35%) of each patient's measured total small bowel length. By tailoring the limb to each patient's anatomy, the study seeks to optimize outcomes by achieving a balance between sufficient weight loss and nutritional safety.
To our knowledge, this is the first single-center study to systematically assess outcomes using this formula-based approach in stapled SADI-S.
Study Objectives
Primary Objective:
To evaluate the impact of bypassing approximately 35% of the measured total small bowel length on weight loss, nutritional outcomes, and postoperative symptoms in patients undergoing SADI-S (either as a primary or revisional procedure).
Secondary Objectives:
To assess the safety and practicality of using a stapled duodeno-ileal anastomosis in all patients.
To analyze correlations between the tailored BPL length and outcomes such as comorbidity remission, postoperative symptoms, and quality of life.
To assess long-term sustainability of weight loss and rates of nutritional deficiency.
Study Design
This is a prospective, single-center, observational study conducted at the Department of Surgery, El Sahel Teaching Hospital, Cairo, Egypt. The study will include 40 adult patients who meet the inclusion criteria and provide informed consent. Participants will undergo either primary SADI-S or revisional SADI-S after previous sleeve gastrectomy, depending on individual indication.
All surgeries will be performed by experienced bariatric surgeons using a standardized five-port laparoscopic approach.
Preoperative Assessment
All candidates will undergo thorough preoperative evaluation, including:
Complete medical history and physical examination.
Anthropometric measurements: height, weight, BMI.
Laboratory testing: fasting glucose, HbA1c (for diabetics), CBC, liver and renal function tests, coagulation profile, thyroid function, and micronutrient baseline panel.
Cardiopulmonary assessment with ECG and echocardiography.
Upper abdominal ultrasound to detect gallstones; concomitant cholecystectomy will be performed when indicated.
For revisional cases, CT virtual gastroscopy and gastric volumetry to assess sleeve anatomy, pouch volume, and exclude twist or stenosis.
Surgical Technique
Sleeve Gastrectomy Component
In primary cases, a 50 French bougie is used for calibration, with complete fundus mobilization and linear stapling from the antrum to the angle of His.
In revisional cases, complete adhesiolysis and pouch resizing are performed, again calibrated over a 50 French bougie.
Intraoperative Measurement of Small Bowel Length
The total small bowel length (TSBL) is measured from the ligament of Treitz to the ileocecal valve.
Two atraumatic bowel graspers marked at 5 and 10 cm intervals are used to measure the bowel in fully stretched segments, counting hand-by-hand.
Markings are placed at 150 cm and 200 cm with clips and sutures to facilitate later localization.
The measurement is typically completed within 8-10 minutes.
Tailoring of Bypass Limb
The biliopancreatic limb (BPL) is tailored to equal approximately 35% of the TSBL.
For patients with TSBL ≤ 480 cm, a fixed 300 cm common limb is retained to avoid malnutrition.
For longer TSBL, the duodeno-ileal anastomosis is created at the point corresponding to 65% of the measured total length from the ileocecal valve.
Duodeno-Ileal Anastomosis (Stapled Technique)
The duodenum is transected 3-4 cm distal to the pylorus using a linear stapler.
The selected ileal segment is brought in an isoperistaltic orientation.
A side-to-side, functional end-to-end stapled anastomosis is performed using a 45-mm linear stapler.
The common enterotomy is closed with a single layer of absorbable running suture.
Air-leak test is performed routinely.
Hemostasis is confirmed.
Drain placement is selective.
Specimen extraction is performed through the umbilical or left upper port.
Postoperative Management
All patients follow a standardized postoperative pathway:
Early ambulation within 6 hours after surgery.
Liquid diet started on postoperative day 1 and advanced as tolerated.
Discharge typically occurs on postoperative day 2-3.
All patients receive lifelong vitamin and mineral supplementation as per international bariatric guidelines.
Follow-Up Schedule
Patients are evaluated at:
1, 3, 6, 9, and 12 months postoperatively, then annually.
At each follow-up, data collected include:
Weight, BMI, and percent excess weight loss (%EWL).
Comorbidity evaluation (diabetes, hypertension, dyslipidemia, sleep apnea, PCOS).
Nutritional laboratory profile (Hb, albumin, vitamin D, calcium, phosphorus, magnesium, ferritin, vitamin B12).
Assessment of gastrointestinal symptoms (reflux, diarrhea, flatulence, dumping, bile reflux).
Quality of life assessment and dietary adherence.
Outcome Measures
Primary Outcomes:
Weight loss effectiveness at 6 months, 1 year, and annually thereafter.
Incidence of postoperative gastrointestinal symptoms.
Secondary Outcomes:
Nutritional outcomes and their correlation with bypassed bowel length.
Resolution rates of metabolic comorbidities.
Safety and feasibility of the stapled duodeno-ileal anastomosis technique.
Data Collection and Analysis
All data will be recorded in a prospective electronic database. Weight loss metrics will be analyzed using %EWL and %TWL. Nutritional markers will be compared across time points and correlated with limb length ratios. Complications will be classified according to the Clavien-Dindo scale.
Continuous variables will be expressed as mean ± SD and analyzed using paired or unpaired t-tests as appropriate. Categorical variables will be analyzed using chi-square tests. Statistical significance will be set at p \< 0.05.
Potential Risks and Benefits
The surgical risks are consistent with standard laparoscopic bariatric procedures and include bleeding, leakage, infection, bowel obstruction, and nutritional deficiencies. However, tailoring the bypass length to individual bowel anatomy is expected to lower the risk of severe malabsorption while maintaining adequate weight loss.
Patients are expected to benefit from improved obesity-related comorbidities, enhanced quality of life, and a durable weight loss profile.
Confidentiality and Data Sharing
All participant data will be de-identified and stored securely. Only authorized investigators will have access to the data.
Individual participant data (IPD) will not be shared publicly due to privacy and institutional regulations but may be available upon reasonable request for meta-analyses with ethics approval.
Study Significance
This study represents a step toward personalized bariatric surgery. By objectively measuring bowel length and tailoring the bypass segment, surgeons can minimize variability and optimize outcomes. The use of a stapled anastomosis further standardizes the procedure, reducing technical variability.
If successful, this tailored SADI-S approach could serve as a model for safe, effective, and individualized metabolic surgery, contributing valuable evidence toward standardization of limb length in malabsorptive procedures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tailored SADI-S
Procedure: Bariatric surgery
Only surgical procedure in the study
Also known as: SADI-S
Weight loss effectiveness
Change in weight
Time frame: 6 months,1year, 2 years, 3 years, 4 years and 5 years
Incidence of postoperative symptoms
Vomiting, diarrhea, weakness, etc.
Time frame: 6 months,1year, 2 years, 3 years, 4 years and 5 years
Nutritional status and its correlation with limb length
Albumin, Na, K, vitamens, etc.
Time frame: 6 months,1year, 2 years, 3 years, 4 years and 5 years
Safety of stapled anastomosis
Anastomosis related complications will include postoperative bleeding requiring intervention (via vital signs, CBC, or imaging), confirmed anastomotic or staple-line leakage or anastomotic stenosis (via imaging or endoscopy) requiring endoscopic or surgical treatment. Results will be reported as the number and percentage of participants who experience ≥1 complication.
Time frame: 6 months,1year, 2 years, 3 years, 4 years and 5 years
Plan to share: No — Individual participant data (IPD) will not be publicly shared because this is a single-center observational study with a relatively small sample size (n=40), which may allow indirect identification of participants despite anonymization. However, de-identified summary data and aggregated results supporting the findings of this study will be available from the corresponding author upon reasonable request for academic and non-commercial purposes.
Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.
Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 30 months is above that.
Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
El-Sahel Teaching Hospital